Full-Time

Head – Clinical Development

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior

No H1B Sponsorship

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD required
  • Background in translational science is a plus.
  • 2+ years of experience in leading clinical development programs in the pharmaceutical industry with a proven record of achievements.
  • Ability to think critically and demonstrate troubleshooting and problem-solving skills.
  • Demonstrated leadership and team building skills as well as the ability to perform effectively in a multi-disciplinary environment.
  • Ability to lead directly and by influence, including strong interpersonal, problem solving, conflict resolution and analytical skills in a matrix environment.
  • Excellent communication skills (oral and written) and organizational skills.
  • Ability to travel internationally and domestically
Responsibilities
  • Provide medical monitoring to assigned neurology clinical trials
  • Provide clinical development leadership for programs that integrate extensive knowledge in clinical science and neurology, and inputs from the global medical community
  • Work closely with Medical Directors, Pharmacology, Drug Discovery, external experts, and investigators to accumulate scientific and medical knowledge necessary to support clinical development plans with a focus on pharmacodynamic endpoints
  • Integrates scientific rationale, regulatory requirements, product development plan, and value to patients and shareholders to build a solid Clinical Development Plan (CDP)
  • Accountable for production of highest quality program related documents, including protocols, IBs, clinical study reports, briefing documents and drug labels
  • Develop and maintain relationships with program counterparts in Research, Regulatory Affairs, Clinical Operations, Statistics and Contract Research Organizations (CROs)
  • Act as the primary Clinical Development interface with internal stakeholders as well as external subject matter experts and alliance partners for the assigned programs
  • Contribute to specific Business Development activities and various organizational initiatives in Clinical Development
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-38%

1 year growth

-33%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.

Help us improve and share your feedback! Did you find this helpful?